CD6: A Promising Drug Target and Biomarker for Cell Division Cycle 6 Homolog
CD6: A Promising Drug Target and Biomarker for Cell Division Cycle 6 Homolog
Cell division cycle (CDC) is a series of critical biological processes that occur in eukaryotic cells, including the process of cell division, DNA replication, and repair. The CDC is composed of three sub-cellular organelles: the centromere, the spindle, and the mitotic catenion. It is responsible for the proper separation of chromosomes during cell division and plays a crucial role in ensuring the genetic integrity of the cell.
Homologs are genetic molecules that encode the same sequence of DNA in different organisms. In the context of cell division, homologs can be useful in understanding the mechanisms of cell division and in the development of new therapeutic strategies. The homolog of interest in this article is CDC6, which is a member of the CDC family.
CDC6: Structure and Function
CDC6 is a small non-coding RNA molecule that plays a critical role in the regulation of cell division. It is a key component of the CDC and is involved in the assembly and function of the spindle. Specifically, CDC6 is a subunit of the spindle complex, which is responsible for organizing the chromosomes during the cytokinesis process.
CDC6 is composed of 216 amino acids and has a molecular weight of 23 kDa. It consists of a nucleotide acid (AUG) that is repeated in the middle of the molecule, as well as a variable number of terminal extensions that form a stem-loop structure in the middle of the molecule. This stem-loop structure is important for CDC6's stability and functions as a binding site for other molecules.
CDC6 functions as a negative regulator of the Rb protein. Rb is a key regulator of the CDC and is involved in the maintenance of chromosomal stability during cell division. When Rb is activated, it promotes the recruitment of CDC6 to the spindle, which in turn promotes the assembly of the spindle complex. However, when Rb is inhibited, CDC6 is unable to bind to the spindle and the assembly of the spindle complex is hindered.
In addition to its role in regulating the CDC, CDC6 has also been shown to play a critical role in the development and progression of cancer. For example, studies have shown that high levels of CDC6 are associated with poor prognosis in various types of cancer, including breast, ovarian, and prostate cancers.
Drug Targeting and Biomarker
The potential of CDC6 as a drug target is due to its involvement in the regulation of cell division and its association with cancer. Researchers are currently exploring the use of small molecules and other compounds to target CDC6 and inhibit its activity. This approach is expected to lead to new therapeutic strategies for the treatment of cancer.
One approach to targeting CDC6 is to use small molecules that can bind to specific regions of the molecule. This approach has been used to develop inhibitors of CDC6, such as the drug tasudol, which is currently in clinical trials for the treatment of ovarian cancer.
Another approach to targeting CDC6 is to use antibodies that can selectively bind to the molecule. This approach has been used to develop monoclonal antibodies (MCAs) that can target CDC6 and are currently being tested in clinical trials for the treatment of various types of cancer.
In addition to its potential as a drug target, CDC6 has also been identified as a potential biomarker for cancer. The expression of CDC6 has been shown to be elevated in various types of cancer, including breast, ovarian, and prostate cancers. This suggests that CDC6 may be a useful biomarker for the diagnosis and monitoring of cancer.
Conclusion
In conclusion, CDC6 is a promising drug target and biomarker for the regulation of cell division and the treatment of cancer. Its involvement in the
Protein Name: Cell Division Cycle 6
Functions: Involved in the initiation of DNA replication. Also participates in checkpoint controls that ensure DNA replication is completed before mitosis is initiated
The "CDC6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC6 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1
